TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00745511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORA102 and Avastin
Description: treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORA102 and Avastin
Description: treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avastin
Description: treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
Study: NCT03014713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dezocine
Description: Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dezocine
Description: Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flubiprofen
Description: Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flubiprofen
Description: Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.1μg/kg/h intravenous administration during the first two days after surgery.
Study: NCT02436031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine
Description: 200 mg administered 2 hours before normal sleep time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Description: 200 mg administered 2 hours before normal sleep time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo-matching desipramine administered 2 hours before normal sleep time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching desipramine administered 2 hours before normal sleep time
Study: NCT04336813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audience Response system
Description: In the lecture hall, G1 was separated from G2, and both groups completed an assessment of written multiple-choice questions (MCQs) scored out of 20, before the lecture. During L1, phone based (ARS) questions (PB-ARS) secretly displayed on the smart phones of the students in G1, and they were allowed to read the question and answer it, while those in parallel arm of the trial (G2) were blinded to those questions and answers. At the end of L1, both groups completed the same written MCQs assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audience Response system
Description: In the lecture hall, G1 was separated from G2, and both groups completed an assessment of written multiple-choice questions (MCQs) scored out of 20, before the lecture. During L1, phone based (ARS) questions (PB-ARS) secretly displayed on the smart phones of the students in G1, and they were allowed to read the question and answer it, while those in parallel arm of the trial (G2) were blinded to those questions and answers. At the end of L1, both groups completed the same written MCQs assessment
Study: NCT01886742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Group
Description: The standard dose of Cefazolin will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weight Based Group
Description: The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
Study: NCT03047096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: intra-Articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid and corticosteroids
Description: intra-Articular injection
Study: NCT03576534

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of prebypass ultrafiltration (PBUF)
Description: In addition to standard of care for cardiopulmonary bypass, in the study arm prebypass ultrafiltration will be performed.
Study: NCT01492725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-arterial Clot Retrieval with Solitaire device
Description: Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: intravenous tissue plasminogen activator (tPA)
Description: Standard care IV tPA therapy administered as per registered product information
Study: NCT03499275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active NMES
Description: Neuromuscular electrical stimulation to the quadriceps muscle

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NMES
Description: Sham neuromuscular electrical stimulation to the quadriceps muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise programme
Description: Home exercise programme. Both arms of the trial receive this intervention.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Home exercise programme
Description: Home exercise programme. Both arms of the trial receive this intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathlessness advice
Description: Breathlessness advice. Both arms of the trial receive this intervention.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Breathlessness advice
Description: Breathlessness advice. Both arms of the trial receive this intervention.
Study: NCT01090154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimzia
Description: Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
Study: NCT01313494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
Study: NCT04160572

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morning sleep schedule
Description: sleep right after night shifts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning sleep schedule
Description: sleep right after night shifts

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evening sleep schedule
Description: sleep before night shifts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening sleep schedule
Description: sleep before night shifts
Study: NCT01298141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: agalsidase alfa
Description: Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)~Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly
Study: NCT04064541

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Visit
Description: Virtual Visit
Study: NCT04791605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Kinematic and kinetic analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Kinematic and kinetic analysis
Study: NCT03415659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HWH340 tablet
Description: 1. single escalating dose study starts from 20 mg as the initial dose until the maximum dose group (520mg) or maximum tolerated dose (MTD) has been reached.~2. multiple-dose study conducted on oral HWH340 tablet BID. The DLTs evaluating period is 4 weeks and the safety evaluation period lasts till 4 weeks after drug withdrawal.~3. dose-expansion study conducted on oral HWH340 tablet BID in 2 to 4 dose groups. Patients with BRCA mutation OR HRD will be assigned to 2 cohort in each dose group.
Study: NCT02737228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG200745 PPA
Description: CG200745 PPA IV every week three times per cycle (4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 intravenously every week three times per cycle (4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg per oral daily per cycle (4 weeks)
Study: NCT02974205

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Jack brace
Description: Rehabilitation after acute isolated PCL rupture with orthosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation after acute isolated PCL rupture without orthosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: össur brace
Description: Rehabilitation after acute isolated PCL rupture
Study: NCT02611128

Intervention type: OTHER
Intervention: Phenotype/genotype assessment
Description: The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
Study: NCT03168919

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Radiation
Description: Standard of care fractionated radiation therapy will be given to the tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Standard of care temozolomide will be given along with radiation therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Four MRI scan will be performed according to the protocol. The first one will be obtained before start of radiation therapy, the second MRI will be obtained after completion of 20 +/- 4 Gy, the third MRI will be obtained after completion of 40 +/- 4 Gy, and the final MRI will be obtained after completion of the radiation therapy.
Study: NCT01273740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External support
Description: Bypass surgery with externally supported graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External support
Description: Bypass surgery with externally supported graft
Study: NCT04122664

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RayOne® Hydrophobic lens 800C
Description: Patients will receive a monofocal, aspheric, hydrophobic acrylic intraocular lens: the RayOne® Hydrophobic lens 800C

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RayOne® Hydrophilic lens 600C
Description: Patients will receive a monofocal aspheric, hydrophilic acrylic intraocular lens: the RayOne® Hydrophilic lens 600C.
Study: NCT02851056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Survivin Vaccine
Description: Pre-transplant vaccination : The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered.~Post-transplant vaccination: The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, HLA-DR+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Cell Transplantation
Description: The participant's own cells are collected from their blood, frozen, and then given back to them after they receive chemotherapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: 13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine. This vaccine will be administered intramuscular (IM) 0.5cc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony Stimulating Factor
Description: After the first survivin vaccination, participants will be mobilized with G-CSF.
Study: NCT01005888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] (C1INH-nf)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] (C1INH-nf)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (saline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Study: NCT00367484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rebif® (clone 484-39)
Description: s.c. administered Rebif®
Study: NCT03408249

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IBDoc calprotectin test
Description: Patients are asked to perform a single IBDoc calprotectin home test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: Patients evaluate the ease-of-use of the test, clearness of test results and comprehensiveness of the instructions for use through a specific questionnaire implementing Likert scales.
Study: NCT02526875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telminuvo®Tab. 40/2.5mg
Description: per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telminuvo®Tab. 40/2.5mg
Description: per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
Study: NCT04919876

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fruit/vegetable supplement (FVS)
Description: The supplement contains polyphenols, carotenoids, and other phytochemicals present in plant foods.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The product does not contain nutrients present in the FVS.
Study: NCT02616315

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone HCl/Bupropion HCl Placebo
Description: Naltrexone/bupropion placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl/Bupropion HCl
Description: Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets
Study: NCT03294291

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: Postoperative pain procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Postoperative pain procedure
Study: NCT04380012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib as interventions were used in patients with HER2-positive advanced colorectal cancer
Study: NCT05139576

Intervention type: DIAGNOSTIC_TEST
Intervention: serum 25OHD testing
Description: Subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those with 25OHD levels \>150 ng/ml were contacted via telephone.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum 25OHD testing
Description: Subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those with 25OHD levels \>150 ng/ml were contacted via telephone.
Study: NCT01514630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Five grams of creatine monohydrate will be administered for eight weeks.
Study: NCT03022045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: risankizumab administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: risankizumab administered by subcutaneous injection
Study: NCT02315079

Intervention type: OTHER
Intervention: Eye inflammation
Description: This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.

Intervention type: OTHER
Intervention: Without eye inflammation
Description: This group will have a regular eye exam with the collection of tears.
Study: NCT02127814

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus reuteri
Description: One chewable tablet of 1E8 CFU L. reuteri, once per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: One chewable tablet of 1E8 CFU L. reuteri, once per day
Study: NCT01447251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PreDx Diabetes Risk Score
Description: The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PreDx Diabetes Risk Score
Description: The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PreDx Diabetes Risk Score
Description: The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.
Study: NCT04380012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib in combination with trastuzumab
Description: Pyrotinib in combination with trastuzumab as interventions were used in patients with HER2-positive advanced colorectal cancer
Study: NCT01573416

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ASSIST-linked brief intervention for hazardous and harmful substance use.
Description: ASSIST-linked brief intervention will be applied to users achieving moderate risk scores in the ASSIST questionnaire. If after randomization are selected to enter the intervention group, they will receive a ten minute counseling carried immediately after the screening instrument. This intervention group will be re-evaluated after 3 months with the same ASSIST screening instrument.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation
Description: Subjects who obtain a moderate risk score in the ASSIST screening questionnaire and after randomization are selected for the control group, will receive a brochure with substance-abuse information without any further conversation about the subject with the caregiver. This observation group will be re-evaluated after 3 months with the same ASSIST screening instrument.
Study: NCT01447251

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PreDx Diabetes Risk Score
Description: The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.
Study: NCT02581228

Intervention type: DEVICE
Intervention: ML-PrediCare

Intervention type: DEVICE
Intervention: ML-PrediCare
Study: NCT01398189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clozapine
Description: C-11 clozapine
Study: NCT03634683

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LioCyx
Description: Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
Study: NCT03861871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine Hydrochloride
Description: Oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. Manufactured by Andersonbrecon, Inc. on behalf of Zogenix International Limited.
Study: NCT00394433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT02920177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma injection
Description: platelet-rich plasma injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog 10 MG/ML Injectable Suspension
Description: 4 mL corticosteroid injection